Insider Selling: Insmed Incorporated (NASDAQ:INSM) CEO Sells 8,218 Shares of Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 8,218 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $66.02, for a total value of $542,552.36. Following the sale, the chief executive officer now owns 376,742 shares of the company's stock, valued at $24,872,506.84. This represents a 2.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Performance

NASDAQ:INSM traded down $0.47 during midday trading on Friday, reaching $65.25. 3,087,759 shares of the company traded hands, compared to its average volume of 1,881,810. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a fifty day moving average price of $71.29 and a 200 day moving average price of $72.44. The firm has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. The firm's quarterly revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.10) EPS. On average, analysts expect that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Truist Financial reaffirmed a "buy" rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. raised their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a report on Friday, November 22nd. Bank of America increased their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. Finally, HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and an average price target of $83.67.

Institutional Trading of Insmed

Several large investors have recently added to or reduced their stakes in INSM. Orion Portfolio Solutions LLC boosted its holdings in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock valued at $2,050,000 after purchasing an additional 9,170 shares during the period. Ally Bridge Group NY LLC boosted its stake in Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock worth $11,011,000 after purchasing an additional 21,833 shares in the last quarter. Vestal Point Capital LP grew its holdings in Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after acquiring an additional 850,000 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in shares of Insmed in the third quarter valued at approximately $35,322,000. Finally, Jennison Associates LLC increased its stake in shares of Insmed by 3.4% in the 3rd quarter. Jennison Associates LLC now owns 769,253 shares of the biopharmaceutical company's stock valued at $56,155,000 after buying an additional 24,973 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.